Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 4/20 | 0.49 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | MOK | Q9UQ07 | 2/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | EGFR | P00533 | 4/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58299 | 0.90 | ACVRL1 (0.62) | ACVRL1MERTKNTRK2NTRK1KMT2A | |
| SCHEMBL5141804 | 0.87 | ACVRL1 (0.45) | ACVRL1MERTKMOKKMT2ALMNA | |
| SCHEMBL58575 | 0.83 | ACVRL1 (0.60) | ACVRL1MERTKNTRK2NTRK1KMT2A | |
| SCHEMBL57964 | 0.83 | ACVRL1 (0.60) | ACVRL1MERTKNTRK2NTRK1KDR | |
| SCHEMBL90886 | 0.83 | ACVRL1 (0.56) | ACVRL1MERTKNTRK2NTRK1KMT2A | |
| SCHEMBL59260 | 0.83 | ACVRL1 (0.57) | ACVRL1MERTKMOKNTRK2NTRK1 | |
| SCHEMBL27768149 | 0.82 | ACVRL1 (0.60) | ACVRL1MERTKNTRK2NTRK1KDR | |
| SCHEMBL59318 | 0.81 | ACVRL1 (0.58) | ACVRL1MERTKNTRK2NTRK1KDR | |
| SCHEMBL59355 | 0.81 | ACVRL1 (0.58) | ACVRL1MERTKNTRK2NTRK1LMNA | |
| SCHEMBL58540 | 0.79 | ACVRL1 (0.57) | ACVRL1MERTKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957485-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Healthcare, LLC (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2007064931-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | claimed |
| EP-1068239-A2 | ANTIOXIDANT PEPTIDES DERIVED FROM APOLIPOPROTEIN A-IV | UNIVERSITY OF CINCINNATI (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999050286-A2 | ANTIOXIDANT PEPTIDES DERIVED FROM APOLIPOPROTEIN A-IV | UNIVERSITY OF CINCINNATI (US) | 1999-10-07 | — | — | WO | claimed |
| US-20080020983-A1 | Peptides with antioxidant and antimicrobial properties | MCCORMACK FRANCIS X JR | 2008-01-24 | — | — | US | disclosed |
| US-7312249-B2 | Vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-25 | — | — | US | disclosed |
| US-7273847-B2 | Peptides with antioxidant and antimicrobial properties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-25 | — | — | US | disclosed |
| EP-1537065-B1 | ANALOGUES OF VITAMIN D | GALDERMA RES & DEV (FR) | 2006-11-02 | — | — | EP | disclosed |
| EP-1303295-B1 | CASEINOGLYCOMACROPEPTIDE FOR INHIBITING ADHESION OF THE PATHOGENIC FLORA OF THE SKIN | NESTLE SA (CH) | 2006-09-13 | — | — | EP | disclosed |
| US-20050182144-A1 | Novel vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-18 | — | — | US | disclosed |
| EP-1537065-A1 | ANALOGUES OF VITAMIN D | Galderma Research & Development, S.N.C. (FR) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020379-A1 | ANALOGUES OF VITAMIN D | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2004-03-11 | — | — | WO | disclosed |
| US-5935585-A | Biaromatic amido compounds and pharmaceutical/cosmetic compositions comprised thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1999-08-10 | — | — | US | disclosed |
| US-5905088-A | SKIN DISORDERS, RHEUMATIC DISEASES, RESPIRATORY SYSTEM OR CARDIOVASCULAR DISORDERS AND OPTHALMOLOGICAL DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1999-05-18 | — | — | US | disclosed |
| US-5849798-A | Polyaromatic heterocyclic compounds and pharmaceutical/cosmetic compositions comprised thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-12-15 | — | — | US | disclosed |
| US-5766610-A | USEFUL FOR TREATMENT OF MAMMALIAN SKIN AND HAIR, RHEUMATISM, RESIPIRATORY SYSTEM DISORDER, CARDIOVASCULAR AND VISION DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-06-16 | — | — | US | disclosed |
| US-5744499-A | Apoptosis-modulating factors influencing the intracellular concentration of methional/malondialdehyde | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-04-28 | — | — | US | disclosed |
| US-5723499-A | Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | C.I.R.D. GALDERMA (FR) | 1998-03-03 | — | — | US | disclosed |
| US-5716624-A | USEFUL FOR TREATING DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, OPTHALMOLOGICAL DISORDERS, AS WELL AS MAMMALIAN SKIN AND HAIR CONDITIONS/DISORDERS | C.I.R.D. GALDERMA (FR) | 1998-02-10 | — | — | US | disclosed |
| US-5709867-A | TREATMENT OF DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, AND OPHTHALMOLOGICAL DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182144-A1 | Novel vitamin D analogues | CYP24A1, CYP2R1, VDR | ACVRL1 2243/4885MERTK 4518/4885MOK 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.